MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte profit margin

Profit margin (net margin) is net income as a percentage of revenue.

MaxCyte's profit margin for the twelve months ending Sep 30, 2026 was -81.4%. For fiscal 2025 it was -135.1%, against -106.3% the year before. The highest annual figure on record is -45.2% in fiscal 2020.

Annual profit margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-135.1%	−28.9
FY2024	Dec 31, 2024	-106.3%	−14.4
FY2023	Dec 31, 2023	-91.8%	−38.6
FY2022	Dec 31, 2022	-53.3%	+3.0
FY2021	Dec 31, 2021	-56.3%	−11.1
FY2020	Dec 31, 2020	-45.2%	+14.5
FY2019	Dec 31, 2019	-59.6%	–

Quarterly profit margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-46.9%	+134.9
Q2 FY2026	Jun 30, 2026	-122.0%	+23.2
Q1 FY2026	Mar 31, 2026	-49.2%	+49.5
Q4 FY2025	Dec 31, 2025	-131.5%	−9.5
Q3 FY2025	Sep 30, 2025	-181.8%	−40.3
Q2 FY2025	Jun 30, 2025	-145.3%	−55.4
Q1 FY2025	Mar 31, 2025	-98.8%	−14.8
Q4 FY2024	Dec 31, 2024	-121.9%	−88.2
Q3 FY2024	Sep 30, 2024	-141.6%	−1.0
Q2 FY2024	Jun 30, 2024	-89.9%	+26.4
Q1 FY2024	Mar 31, 2024	-84.0%	+42.9
Q4 FY2023	Dec 31, 2023	-33.7%	+5.0
Q3 FY2023	Sep 30, 2023	-140.6%	−80.1
Q2 FY2023	Jun 30, 2023	-116.2%	−30.3
Q1 FY2023	Mar 31, 2023	-126.9%	−91.8
Q4 FY2022	Dec 31, 2022	-38.7%	+9.3
Q3 FY2022	Sep 30, 2022	-60.5%	−34.0
Q2 FY2022	Jun 30, 2022	-86.0%	−23.8
Q1 FY2022	Mar 31, 2022	-35.1%	+74.3
Q4 FY2021	Dec 31, 2021	-48.0%	−16.9
Q3 FY2021	Sep 30, 2021	-26.4%	+19.4
Q2 FY2021	Jun 30, 2021	-62.2%	−3.9
Q1 FY2021	Mar 31, 2021	-109.4%	–
Q4 FY2020	Dec 31, 2020	-31.1%	–
Q3 FY2020	Sep 30, 2020	-45.8%	–
Q2 FY2020	Jun 30, 2020	-58.3%	–